Trial Profile
NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImmunityBio; NantKwest
- 05 Jul 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2019).
- 29 Jan 2020 Results presented in the CytRx Corporation Media Release.
- 14 Jul 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.